Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Resch

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Opinion in Urology|November 10, 2017
Biomarkers for immunotherapy in urological cancersKilian M Gust, Irene Resch, David D'Andrea
Memo|April 3, 2018
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancerIrene Resch, Shahrokh F Shariat, Kilian M Gust
Aktuelle Urologie|April 3, 2025
[Gender-specific differences in urological tumours]Julia Weiss, Ekaterina Laukhtina, Irene Resch, et al.
Translational Andrology and Urology|November 22, 2021
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literatureKilian M Gust, Irene Resch, David D'Andrea, et al.
Current Opinion in Urology|January 24, 2020
An update on systemic therapy for penile cancerIrene Resch, Mohammad Abufaraj, Nicolai A Hübner, et al.
Urologia Internationalis|July 13, 2025
Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and AbirateroneMoustafa Elleisy, Irene Resch, Ozan Yurdakul, et al.
Current Opinion in Urology|May 27, 2020
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancerKilian M Gust, Katharina Rebhan, Irene Resch, et al.
Current Opinion in Urology|May 27, 2020
The role of taxane-based chemotherapy in the treatment of prostate cancerNicolai A Huebner, Shahrokh F Shariat, Irene Resch, et al.
Urologia Internationalis|August 9, 2018
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer, Andrea Mari, David D'Andrea, et al.
Current Opinion in Urology|March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Urology|November 10, 2017
Biomarkers for immunotherapy in urological cancersKilian M Gust, Irene Resch, David D'Andrea
Memo|April 3, 2018
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancerIrene Resch, Shahrokh F Shariat, Kilian M Gust
Aktuelle Urologie|April 3, 2025
[Gender-specific differences in urological tumours]Julia Weiss, Ekaterina Laukhtina, Irene Resch, et al.
Translational Andrology and Urology|November 22, 2021
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literatureKilian M Gust, Irene Resch, David D'Andrea, et al.
Current Opinion in Urology|January 24, 2020
An update on systemic therapy for penile cancerIrene Resch, Mohammad Abufaraj, Nicolai A Hübner, et al.
Urologia Internationalis|July 13, 2025
Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and AbirateroneMoustafa Elleisy, Irene Resch, Ozan Yurdakul, et al.
Current Opinion in Urology|May 27, 2020
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancerKilian M Gust, Katharina Rebhan, Irene Resch, et al.
Current Opinion in Urology|May 27, 2020
The role of taxane-based chemotherapy in the treatment of prostate cancerNicolai A Huebner, Shahrokh F Shariat, Irene Resch, et al.
Urologia Internationalis|August 9, 2018
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer, Andrea Mari, David D'Andrea, et al.
Current Opinion in Urology|March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
Pageof 3